News | July 17, 2024
Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Shoff brings over 30 years of international experience in in vitro diagnostics, healthcare distribution and veterinary diagnostics
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
The company will address these observations within the stipulated timeline
The company is planning to expand its plant capacity in in Vapi
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Subscribe To Our Newsletter & Stay Updated
